Colostrum as oral immune therapy to promote neonatal health

Sheila M Gephart, Michelle Weller

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

It is well known that the immune response is blunted and underdeveloped in the premature infant, but human milk supports the infant's growth, function, and effectiveness. Thus, own mother's colostrum (OMC) administered oropharyngeally has potential to deliver oral immune therapy (C-OIT) even before enteral feedings have begun. Colostrum interacts with lymphoid tissue in the oropharynx and gut. Colostrum as oral immune therapy is delivered by swabbing the cheeks in the first days of life. Little formal study has evaluated its effectiveness. However, small studies demonstrate that it is a practice that is safe, feasible, and well tolerated even by the smallest premature infants. Encouraging preliminary evidence supports the effect of C-OIT to reduce the time to full enteral feedings. Effects on other outcomes is unclear, in part because existing studies are underpowered to detect significant differences on outcomes like ne crotizing enterocolitis, sepsis, and death. Another limitation in the evidence base is that adherence to the intervention and the number of doses of colostrum infants received in the studies is not consistently made clear. More well-designed studies are needed to demonstrate the impact on neonatal complications and how C-OIT supports the infant's immune development. Quality improvement and time series reports of differences pre- and postimplementation of OMC given orally should minimally include statistics for adherence to the intervention and/or the number of doses an infant received as a covariate. Even so, OMC is an immune therapy that poses little risk yet offers likely cost-effective benefit for vulnerable infants.

Original languageEnglish (US)
Pages (from-to)44-51
Number of pages8
JournalAdvances in Neonatal Care
Volume14
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Colostrum
Mothers
Enteral Nutrition
Premature Infants
Therapeutics
Enterocolitis
Oropharynx
Cheek
Lymphoid Tissue
Human Milk
Child Development
Quality Improvement
Cost-Benefit Analysis
Infant Health
Sepsis
Growth

Keywords

  • Breast milk
  • Colostrum
  • Extremely low birth weight
  • Health promotion
  • Human milk
  • Infection prevention
  • Neonatal intensive care
  • Neonate
  • Nutrition
  • Oral immune therapy
  • Very low birth weight

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Colostrum as oral immune therapy to promote neonatal health. / Gephart, Sheila M; Weller, Michelle.

In: Advances in Neonatal Care, Vol. 14, No. 1, 2014, p. 44-51.

Research output: Contribution to journalArticle

@article{3e6a138b04264bbfa109ccc3f395ca1b,
title = "Colostrum as oral immune therapy to promote neonatal health",
abstract = "It is well known that the immune response is blunted and underdeveloped in the premature infant, but human milk supports the infant's growth, function, and effectiveness. Thus, own mother's colostrum (OMC) administered oropharyngeally has potential to deliver oral immune therapy (C-OIT) even before enteral feedings have begun. Colostrum interacts with lymphoid tissue in the oropharynx and gut. Colostrum as oral immune therapy is delivered by swabbing the cheeks in the first days of life. Little formal study has evaluated its effectiveness. However, small studies demonstrate that it is a practice that is safe, feasible, and well tolerated even by the smallest premature infants. Encouraging preliminary evidence supports the effect of C-OIT to reduce the time to full enteral feedings. Effects on other outcomes is unclear, in part because existing studies are underpowered to detect significant differences on outcomes like ne crotizing enterocolitis, sepsis, and death. Another limitation in the evidence base is that adherence to the intervention and the number of doses of colostrum infants received in the studies is not consistently made clear. More well-designed studies are needed to demonstrate the impact on neonatal complications and how C-OIT supports the infant's immune development. Quality improvement and time series reports of differences pre- and postimplementation of OMC given orally should minimally include statistics for adherence to the intervention and/or the number of doses an infant received as a covariate. Even so, OMC is an immune therapy that poses little risk yet offers likely cost-effective benefit for vulnerable infants.",
keywords = "Breast milk, Colostrum, Extremely low birth weight, Health promotion, Human milk, Infection prevention, Neonatal intensive care, Neonate, Nutrition, Oral immune therapy, Very low birth weight",
author = "Gephart, {Sheila M} and Michelle Weller",
year = "2014",
doi = "10.1097/ANC.0000000000000052",
language = "English (US)",
volume = "14",
pages = "44--51",
journal = "Advances in Neonatal Care",
issn = "1536-0903",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Colostrum as oral immune therapy to promote neonatal health

AU - Gephart, Sheila M

AU - Weller, Michelle

PY - 2014

Y1 - 2014

N2 - It is well known that the immune response is blunted and underdeveloped in the premature infant, but human milk supports the infant's growth, function, and effectiveness. Thus, own mother's colostrum (OMC) administered oropharyngeally has potential to deliver oral immune therapy (C-OIT) even before enteral feedings have begun. Colostrum interacts with lymphoid tissue in the oropharynx and gut. Colostrum as oral immune therapy is delivered by swabbing the cheeks in the first days of life. Little formal study has evaluated its effectiveness. However, small studies demonstrate that it is a practice that is safe, feasible, and well tolerated even by the smallest premature infants. Encouraging preliminary evidence supports the effect of C-OIT to reduce the time to full enteral feedings. Effects on other outcomes is unclear, in part because existing studies are underpowered to detect significant differences on outcomes like ne crotizing enterocolitis, sepsis, and death. Another limitation in the evidence base is that adherence to the intervention and the number of doses of colostrum infants received in the studies is not consistently made clear. More well-designed studies are needed to demonstrate the impact on neonatal complications and how C-OIT supports the infant's immune development. Quality improvement and time series reports of differences pre- and postimplementation of OMC given orally should minimally include statistics for adherence to the intervention and/or the number of doses an infant received as a covariate. Even so, OMC is an immune therapy that poses little risk yet offers likely cost-effective benefit for vulnerable infants.

AB - It is well known that the immune response is blunted and underdeveloped in the premature infant, but human milk supports the infant's growth, function, and effectiveness. Thus, own mother's colostrum (OMC) administered oropharyngeally has potential to deliver oral immune therapy (C-OIT) even before enteral feedings have begun. Colostrum interacts with lymphoid tissue in the oropharynx and gut. Colostrum as oral immune therapy is delivered by swabbing the cheeks in the first days of life. Little formal study has evaluated its effectiveness. However, small studies demonstrate that it is a practice that is safe, feasible, and well tolerated even by the smallest premature infants. Encouraging preliminary evidence supports the effect of C-OIT to reduce the time to full enteral feedings. Effects on other outcomes is unclear, in part because existing studies are underpowered to detect significant differences on outcomes like ne crotizing enterocolitis, sepsis, and death. Another limitation in the evidence base is that adherence to the intervention and the number of doses of colostrum infants received in the studies is not consistently made clear. More well-designed studies are needed to demonstrate the impact on neonatal complications and how C-OIT supports the infant's immune development. Quality improvement and time series reports of differences pre- and postimplementation of OMC given orally should minimally include statistics for adherence to the intervention and/or the number of doses an infant received as a covariate. Even so, OMC is an immune therapy that poses little risk yet offers likely cost-effective benefit for vulnerable infants.

KW - Breast milk

KW - Colostrum

KW - Extremely low birth weight

KW - Health promotion

KW - Human milk

KW - Infection prevention

KW - Neonatal intensive care

KW - Neonate

KW - Nutrition

KW - Oral immune therapy

KW - Very low birth weight

UR - http://www.scopus.com/inward/record.url?scp=84900454849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900454849&partnerID=8YFLogxK

U2 - 10.1097/ANC.0000000000000052

DO - 10.1097/ANC.0000000000000052

M3 - Article

C2 - 24472888

AN - SCOPUS:84900454849

VL - 14

SP - 44

EP - 51

JO - Advances in Neonatal Care

JF - Advances in Neonatal Care

SN - 1536-0903

IS - 1

ER -